Skip to content
Search

Latest Stories

LloydsPharmacy seeks tangible support from institutional landlords

LloydsPharmacy has asked its health centre landlords to recognise the impact of reduced footfall and renegotiate unsustainable rents or risk further closures of unviable pharmacies.

Having already exited 99 community pharmacies in the last 12 months “as a result of mounting cost pressures and declining footfall”, LloydsPharmacy is appealing to some of its largest landlords as they “fail to acknowledge the harsh reality living with this pandemic is having on community pharmacies”.


Citing findings from a recent report commissioned by the National Pharmacy Association which revealed up to 72 per cent of English pharmacies will be in deficit by 2024 under the current funding, the multiple argued that keeping its doors open during the pandemic had come at a cost.

Chris Keen, McKesson UK’s chief financial officer, said: “As we deal with the second wave of Covid-19, some of our landlords continue to refuse to engage in discussions about unsustainable rents.

"Many health centre landlords base their rents on the number of patients on their register, but these patients are currently being encouraged not to visit sites as GPs provide video and telephone consultations.

"Some institutional landlords have engaged to discuss alternative solutions but the majority, including NHS Property Services, are refusing to recognise the impact of reduced footfall. This is clearly unsustainable and puts at risk our ability to continue providing vital healthcare services to the communities we serve.”

After several failed attempts to engage in rent negotiations with NHS Property Services, LloydsPharmacy says it is now insisting on a 25 per cent discount to the rent in these locations.

Keen added: “Community pharmacy has proven its value on the frontline of the NHS, supporting patients in their communities. Institutional landlords should not be insisting on unsustainable and indefensible high rents, which will only impact on our ability to provide patients with essential access to healthcare. We need our larger landlords to acknowledge this and provide more tangible support during these turbulent times. I’d hope their interest – just like ours – is in a sustainable and long-term business.”

In response, a spokesperson for NHS Property Services told Pharmacy Business: “As an organisation owned by the Department for Health and Social Care, it is vital that NHS Property Services obtain best value for patients and the public. All monies generated are invested directly back into the NHS estate for the benefit of patients.

"We recognise the challenging trading environment which small businesses and larger organisations, such as McKesson, operate in. As such, in early November we wrote back to the CEO of McKesson UK (owner of LloydsPharmacy) to offer a variety of practical and tangible solutions, including a bespoke site-by-site approach to ensure that communities retain these vital services. We have not received a response to our proposals.”

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less